Now Enrolling Learn More Now Enrolling Learn More Now Enrolling Learn More Latest News Aug 10, 2020 Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates View Press Release Jul 10, 2020 Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting View Press Release Jul 9, 2020 Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer View Press Release View All Our inspiration Learn More Pipeline Our clinical-stage therapies are designed to deliver functional copies of affected genes to cells using gene transfer technologies. Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-101 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). Learn More Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
